ProCE Banner Activity

Selection and Sequencing of Available, New, and Emerging Agents for Relapsed/Refractory DLBCL

Slideset Download
Download these slides from a live symposium to gain more insight into the selection and sequencing of therapies in relapsed/refractory DLBCL.

Released: June 05, 2022

Expiration: June 04, 2023

Share

Faculty

Jeremy S Abramson

Jeremy S Abramson, MD, MMSc

Director, Center for Lymphoma
Mass General Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Bristol Myers Squibb

Genmab US, Inc.

Incyte Corporation

Lilly

Faculty Disclosure

Primary Author

Jeremy S Abramson, MD, MMSc

Director, Center for Lymphoma
Mass General Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Jeremy S. Abramson, MD, MMSc, has disclosed that he has received consulting fees from AbbVie, AstraZeneca, BeiGene, Bluebird, Bristol-Myers Squibb, Century, Epizyme, Genentech, Genmab, Incyte, Kite, Kymera, Lilly, MorphoSys, Mustang, Ono, and Regeneron.